Fulvestrant + Capivasertib + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Trial Timeline
Apr 16, 2020 → Jun 22, 2026
NCT ID
NCT04305496About Fulvestrant + Capivasertib + Placebo
Fulvestrant + Capivasertib + Placebo is a phase 3 stage product being developed by AstraZeneca for Locally Advanced (Inoperable) or Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04305496. Target conditions include Locally Advanced (Inoperable) or Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04305496 | Phase 3 | Active |
Competing Products
20 competing products in Locally Advanced (Inoperable) or Metastatic Breast Cancer